1. |
Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
|
2. |
European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL]. [2020-12-01].
|
3. |
US FDA. Vimpat@(lacosamide): highlights of prescribing information [EB/OL]. [2020-11-01].
|
4. |
French JA, Cleary E, Dlugos D, et al. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years. Epilepsia, 2022, 63(10): 2664-2670.
|
5. |
Harris JA, Murphy JA. Lacosamide and epilepsy. CNS Neurosci Ther, 2011, 17(6): 678-682.
|
6. |
Patyar S, Medhi B. Lacosamide, a newer antiepileptic. Neurosciences, 2010, 15(1): 3-6.
|
7. |
Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 is involved in regulation of mitochondrial morphology and motility in neurons. Cells, 2021, 10(10): 2781.
|
8. |
Toupin JF, Lortie A, Major P, et al. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord, 2015, 17(4): 436-443.
|
9. |
May TW, Brandt C, Helmer R, et al. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy. Epilepsia, 2015, 56(7): 1134-1140.
|
10. |
Ishikawa N, Eguchi Y, Izumo H, et al. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study. Epilepsy Behav, 2022, 129: 108614.
|
11. |
Akbar A, Harthan AA, Creeden S, et al. Response of focal refractory status epilepticus to lacosamide in an infant. BMJ Case Rep, 2022, 15(4): e249948.
|
12. |
冯隽, 汤继宏, 张兵兵, 等. 拉考沙胺单药治疗儿童良性癫痫伴中央颞区棘波的临床分析. 癫痫杂志, 2021, 7(6): 477-480.
|
13. |
Okanishi T, Fujii Y, Sakuma S, et al. Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. Brain Dev, 2022, 44(6): 380-385.
|
14. |
Flor-Hirsch H, Heyman E, Livneh A, et al. Lacosamide for SCN2A-related intractable neonatal and infantile seizures. Epileptic Disord, 2018, 20(5): 440-446.
|
15. |
廖红梅, 康庆云, 吴丽文, 等. 拉考沙胺在低龄婴儿钠离子通道相关癫痫中的应用. 中华神经科杂志, 2022, 55(8): 826-833.
|
16. |
Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf, 2020, 19(2): 131-138.
|
17. |
Brodie MJ. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs, 2015, 29(11): 893-904.
|
18. |
Stephen LJ, Kelly K, Parker P, et al. Adjunctive lacosamide: 5 years clinical experience. Epilepsy Res, 2014, 108: 1385-1391.
|
19. |
Shepard PW, St Louis EK. Seizure treatment in transplant patients. Curr Treat Options Neurol, 2012, 14(4): 332-347.
|
20. |
Yang C, Yang Y, Peng Y, et al. Efficacy and safety of lacosamide in pediatric patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav, 2022, 134: 108781.
|